Association between Exposure to Beta 2 Agonists and Corticosteroids and Acquiring Benign Joint Hypermobility Syndrome among Asthmatic Patients: a Case-Control Study


Background:Beta2 (β2) agonists as relievers and corticosteroids as controllers are the mainstay drugs for asthma treatment. Benign Joint Hypermobility Syndrome (BJHS) is a connective tissue disorder with musculoskeletal symptoms.

We had examined the possible association between the use of β2 agonists and corticosteroids and acquiring BJHS in asthmatic patients.

Methods:This was a case-control, hospital-based study including a group of asthmatics who had BJHS (cases), compared with a matched group of asthmatics without BJHS (controls) for the β2 agonists and corticosteroids past and current pattern of use. Information was collected by face-to-face interview and clinical examination and from subjects’ medical records using pre-structured questionnaire. BJHS diagnosis was based on the revised Brighton criteria. Asthma severity was reflected by a score, which was calculated from the asthma questionnaire. Comparison of exposure was done by Calculation of Odds Ratio.


Development of BJHS was found to be significantly associated with chronicity of asthma of average duration of 13.2 years, and hence to prolonged use of β2 agonists and/or corticosteroids (OR 1.019; 95% CI 0.999 - 1.039, P=0.006)

Exposure to β2 agonist and corticosteroid (87 and 79 cases and controls respectively P=0.05)high asthma score (42.9 ± 9.8 and 40.4 ± 8.3 among cases and controls respectively, P=0.011) were significantly associated with the development of BJHS.

[1] L. Yang, H. X. Bai, X. Huang, A. M. Lee, X. Tang, and P. Zhang, Brain biopsy in atypical dementia and primary angiitis of the central nervous system, Human Pathology, 51,146–147, (2016).

[2] , (2011). Paris, France: The International Union Against Tuberculosis and Lung Disease, 2011. 20 June 2016.

[3] N. Ait-Khaled, J. Odhiambo, N. Pearce, K. S. Adjoh, I. A. Maesano, B. Benhabyles, Z. Bouhayad, E. Bahati, L. Camara, C. Catteau, A. El Sony, F. O. Esamai, I. E. Hypolite, K. Melaku, O. A. Musa, L. Ng’ang’a, B. O. Onadeko, O. Saad, M. Jerray, J. M. Kayembe, N. B. Koffi, F. Khaldi, C. Kuaban, K. Voyi, J. M’Boussa, O. Sow, O. Tidjani, and H. J.
Zar, Prevalence of symptoms of asthma, rhinitis and eczema in 13- to 14-year-old children in Africa: The International Study of Asthma and Allergies in Childhood Phase III, Allergy: European Journal of Allergy and Clinical Immunology, 62, no. 3, 247–258, (2007).

[4] , BTS/SIGN Asthma Guideline (2014). information/asthma/btssign-asthma-guideline-2014/. Accessed 2 July 2015.

[5] HA. Boushy, Drugs Used in Asthma. In: Katzung BG, Masters SB, Trevor AJ, editors. (2009). Basic and Clinical Pharmacology, 11th ed. USA: McGraw Hill;. p. 344-347.

[6] MR. Simpson, Benign joint hypermobility syndrome: evaluation, diagnosis, and management, The Journal of the American Osteopathic Association, 106, no. 9, 531– 536, (2006).

[7] R. Grahame, HA. Bird, and A. Child, The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS), J Rheumatol, 27, no. 7, 1777–1779, (1998).

[8] D. B. Everman and N. H. Robin, Hypermobility syndrome., Pediatrics in review / American Academy of Pediatrics, 19, no. 4, 111–117, (1998).

[9] L.-G. Larsson, J. Baum, G. S. Mudholkar, and G. D. Kollia, Benefits and disadvantages of joint hypermobility among musicians, The New England Journal of Medicine, 329, no. 15, 1079–1082, (1993).

[10] N. Adib, K. Davies, R. Grahame, P. Woo, and K. J. Murray, Joint hypermobility syndrome in childhood. A not so benign multisystem disorder? Rheumatology, 44, no. 6, 744–750, (2005).

[11] M. Castori, Ehlers-Danlos Syndrome, Hypermobility Type: An Underdiagnosed Hereditary Connective Tissue Disorder with Mucocutaneous, Articular, and Systemic Manifestations, ISRN Dermatology, 2012, 1–22, (2012).

[12] A.-M. Malfait, A. S. Malik, L. Marinova-Mutafchieva, D. M. Butler, R. N. Maini, and M. Feldmann, The β2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: Mechanisms of action, The Journal of Immunology, 162, no. 10, 6278–6283, (1999).

[13] P. Aránguiz-Urroz, J. Canales, M. Copaja, R. Troncoso, J. M. Vicencio, C. Carrillo, H. Lara, S. Lavandero, and G. Díaz-Araya, Beta2-adrenergic receptor regulates cardiac fibroblast autophagy and collagen degradation, Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease, 1812, no. 1, 23–31, (2011).

[14] A. W. Morgan, S. B. Pearson, S. Davies, H. C. Gooi, and H. A. Bird, Asthma and airways collapse in two heritable disorders of connective tissue, Annals of the Rheumatic Diseases, 66, no. 10, 1369–1373, (2007).

[15] E. Soyucen and F. Esen, Benign joint hypermobility syndrome: A cause of childhood asthma? Medical Hypotheses, 74, no. 5, 823–824, (2010).

[16] F. N. Birrell, A. O. Adebajo, B. L. Hazleman, and A. J. Silman, High prevalence of joint laxity in west africans, Rheumatology, 33, no. 1, 56–59, (1994).

[17] Z. S. Al-rawi, A. J. Al-aszawi, and T. Al-chalabi, Joint mobility among university students in Iraq, Rheumatology, 24, no. 4, 326–331, (1985).

[18] F. Biro, H. L. Gewanter, and J. Baum, THE HYPERMOBILITY SYNDROME, Journal of Pediatric Orthopaedics, 4, no. 2, p. 265, (1984).

[19] M. G. Hall, W. R. Ferrell, R. D. Sturrock, D. L. Hamblen, and R. H. Baxendale, The effect of the hypermobility syndrome on knee joint proprioception, British Journal of Rheumatology, 34, no. 2, 121–125, (1995).

[20] A. J. Hakim, L. F. Cherkas, R. Grahame, T. D. Spector, and A. J. MacGregor, The genetic epidemiology of joint hypermobility: a population study of female twins, Arthritis & Rheumatism, 50, no. 8, 2640–2644, (2004).

[21] Inc. GlaxoSmithKline, Salbutamol sulphate inhalation aerosol, PRODUCT MONOGRAPH April, 29, Article ID 171564, (2014).,

[22] P. Klemp, S. M. Williams, and S. A. Stansfield, Articular mobility in Maori and European New Zealanders, Rheumatology, 41, no. 5, 554–557, (2002).

[23] M. B. Mishra, P. Ryan, P. Atkinson, H. Taylor, J. Bell, D. Calver, I. Fogelman, A. Child, G. Jackson, J. B. Chambers, and R. Grahame, Extra-articular features of benign joint hypermobility syndrome, British Journal of Rheumatology, 35, no. 9, 861–866, (1996).